- Home
- NXTC vs LPCN Comparison
NXTC vs LPCN Comparison
Compare NXTC & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- LPCN
- Stock Information
- Founded
- NXTC 2015
- LPCN 1997
- Country
- NXTC United States
- LPCN United States
- Employees
- NXTC N/A
- LPCN N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- LPCN Health Care
- Exchange
- NXTC Nasdaq
- LPCN Nasdaq
- Market Cap
- NXTC 13.9M
- LPCN 16.1M
- IPO Year
- NXTC 2019
- LPCN N/A
- Fundamental
- Price
- NXTC $0.48
- LPCN $3.29
- Analyst Decision
- NXTC Strong Buy
- LPCN Strong Buy
- Analyst Count
- NXTC 2
- LPCN 2
- Target Price
- NXTC $3.50
- LPCN $9.00
- AVG Volume (30 Days)
- NXTC 336.1K
- LPCN 59.4K
- Earning Date
- NXTC 07-31-2025
- LPCN 08-07-2025
- Dividend Yield
- NXTC N/A
- LPCN N/A
- EPS Growth
- NXTC N/A
- LPCN N/A
- EPS
- NXTC N/A
- LPCN N/A
- Revenue
- NXTC N/A
- LPCN $3,674,834.00
- Revenue This Year
- NXTC N/A
- LPCN N/A
- Revenue Next Year
- NXTC N/A
- LPCN N/A
- P/E Ratio
- NXTC N/A
- LPCN N/A
- Revenue Growth
- NXTC N/A
- LPCN N/A
- 52 Week Low
- NXTC $0.22
- LPCN $2.68
- 52 Week High
- NXTC $1.82
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- NXTC 44.82
- LPCN 51.52
- Support Level
- NXTC $0.45
- LPCN $3.13
- Resistance Level
- NXTC $0.51
- LPCN $3.53
- Average True Range (ATR)
- NXTC 0.07
- LPCN 0.24
- MACD
- NXTC -0.01
- LPCN 0.01
- Stochastic Oscillator
- NXTC 3.24
- LPCN 48.33
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.